(19)
(11) EP 4 518 883 A1

(12)

(43) Date of publication:
12.03.2025 Bulletin 2025/11

(21) Application number: 23772127.9

(22) Date of filing: 08.09.2023
(51) International Patent Classification (IPC): 
A61K 38/18(2006.01)
A61P 9/02(2006.01)
C12N 5/10(2006.01)
A01K 67/027(2024.01)
A61P 9/04(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 38/18; A61P 9/04; A61P 9/02; A01K 67/027; A01K 2207/30; A01K 2227/105; A01K 2267/0375; A01K 2207/35; A01K 67/0276; A01K 2217/075
(86) International application number:
PCT/EP2023/074803
(87) International publication number:
WO 2024/052563 (14.03.2024 Gazette 2024/11)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA
Designated Validation States:
KH MA MD TN

(30) Priority: 08.09.2022 US 202263374942 P

(71) Applicants:
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    55216 Ingelheim am Rhein (DE)
  • Medizinische Hochschule Hannover
    30625 Hannover (DE)

(72) Inventors:
  • WOLLERT, Kai Christoph
    30177 Hannover (DE)
  • WANG, Yong
    30629 Hannover (DE)

(74) Representative: Zwicker, Jörk 
ZSP Patentanwälte PartG mbB Hansastraße 32
80686 München
80686 München (DE)

   


(54) MYELOID-DERIVED GROWTH FACTOR FOR USE IN TREATING CARDIOGENIC SHOCK